wenbo Wu

Dr. wenbo Wu

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SJShiyu Ji
Shiyu Ji
WWwenbo Wu
wenbo Wu
QJQi Jiang
Qi Jiang
Prostate cancer stands as one of the most prevalent malignancies afflicting men worldwide. The tumor microenvironment plays a pivotal role in tumor progression, comprising various cell types including endothelial cells, tumor-associated fibroblasts, and macrophages. Recent accumulating evidence underscores the indispensable contribution of endothelial cells to prostate cancer development. Both endothelial cells and tumor cells release a multitude of factors that instigate angiogenesis, metastasis, and even drug resistance in prostate cancer. These factors serve as regulators within the tumor microenvironment and represent potential therapeutic targets for managing prostate cancer. In this review, we provide an overview of the crucial functions of endothelial cells in angiogenesis, metastasis, and drug resistance, and their prospective therapeutic applications in combating this disease.

7 June 2023 in Cancer Medicine
Verified
Journal Article
Open access
WWwenbo Wu
wenbo Wu
LCLei Chen
Lei Chen
GJGaoZhen Jia
GaoZhen Jia
QTQiLin Tang
QiLin Tang
BHBangmin Han
Bangmin Han
HLHaitao Liu
Haitao Liu
Background: Improving the potency of immune response is paramount among issues concerning immunotherapy of muscle‐invasive bladder cancer (MIBC).Methods: On the basis of immune subtypes, we investigated possible molecular mechanisms involved in tumor immune escape in MIBC. According to the 312 immune‐related genes, three MIBC immune subtypes were clustered.Results: Cluster 2 subtype is characterized by FGFR3 mutations and has a better clinical prognosis. However, the expression levels of MHC‐I and immune checkpoints genes were the lowest, indicating that this subtype is subject to immune escape and has a low response rate to immunotherapy. Bioinformatics analysis and immunofluorescence staining of clinical samples revealed that the FGFR3 is involved in the immune escape in MIBC. Besides, after FGFR3 knockout with siRNA in RT112 and UMUC14 cells, the TLR3/NF‐kB pathway was significantly activated and was accompanied by upregulation of MHC‐I and PD‐L1 gene expression. Furthermore, the use of TLR3 agonists poly(I:C) can further improve the effect.Conclusion: Together, our results suggest that FGFR3 might involve in immunosuppression by inhibition of NF‐kB pathway in BC. Considering that TLR3 agonists are currently approved for clinical treatment as immunoadjuvants, our study might provide more insights for improving the efficacy of immunotherapy in MIBC.

4 November 2025 in Cell & Bioscience
Verified
Journal Article
Open access
PDF file
SJShiyu Ji
Shiyu Ji
ZXZhen Xi
Zhen Xi
TLTiewen Li
Tiewen Li
GJGaozhen Jia
Gaozhen Jia
YZYu Zhang
Yu Zhang
QJQi Jiang
Qi Jiang
Cancer-associated fibroblasts (CAFs) exhibit heterogeneity and play diverse roles in prostate cancer (PCa) progression, yet their specific impact via lactate metabolism remains unexplored. This study identifies a CAFs lactate metabolism-associated transcriptomic signature (CLS) through multi-omics analysis and establishes a Lactate Metabolism-Related Clinical Prognostic Index (LMCAFCPI) using machine learning. Lactate metabolism genes from MsigDB, were used to derive CLS from single-cell RNA sequencing (scRNA-seq). Unsupervised clustering divided samples into two risk subgroups, and GSVA and ssGSEA assessed biological functions and immune features. The LMCAFCPI demonstrated superior prognostic performance. A nomogram incorporating Gleason grade, PSA, T-stage, and LMCAFCPI showed stable biochemical recurrence (BCR) prediction. The study also revealed positive correlations between LMCAFCPI and specific immune cells, and validated signature genes in cellular models. CUT-TAG sequence confirmed PA2G4 knockdown in CAFs suppresses PCa proliferation and metastasis by inhibit H3K18la. Overall, LMCAFCPI offers a novel prognostic tool for PCa management and highlights potential targets for future research, with PA2G4 emerging as a potential therapeutic target due to its inhibition of H3K18la in PCa.